Biogen takes second royalties victory in blow for Forward Pharma

Danish biotech company Forward Pharma has once again lost out to US-based firm Biogen, after the European Patent Office decided to uphold the ruling that royalties are not owed.  

The European Patent Office, Munich. | Photo: Frank Leonhardt/AP/Ritzau Scanpix

US-based Biogen can celebrate another victory in its drawn-out legal battle against Forward Pharma.

Forward Pharma announced in a press release that the board of appeals at the European Patent Office has rejected the company's attempt to overturn the annulment of its European patent, EP2801355.

Read the whole article

Get 14 days free access.

No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs